Abstracts tagged "Vasculitis"

Abstract Number: 2499 • ACR Convergence 2024
Description of Patients with Kawasaki Disease Shock Syndrome at a Large Tertiary Center
Jessica Nguyen¹, Danielle Guffey², Andrea Ramirez¹, Jamie Lai³, Tiphanie Vogel¹, S. Kristen Sexson Tejtel¹, Cagri Yildirim-Toruner⁴ and Marietta De Guzman¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, ³Baylor College of Medicine, The Woodlands, TX, ⁴Baylor College of Medicine/ Texas Children's Hospital, Houston, TX
Background/Purpose: Kawasaki disease shock syndrome (KDSS) is a phenotype of Kawasaki disease (KD) associated with higher rates of refractory KD (RKD) and coronary artery aneurysms…
Abstract Number: 2523 • ACR Convergence 2024
Biological Treatment May Be an Option as First Steroid-Sparing Agent in a Subgroup of Young Takayasu Arteritis Patients with Prominent Acute Phase Reactants and Constitutional Symptoms
Sema Kaymaz-Tahra¹, Ozun Bayindir Tsechelidis², Burak Ince³, Ozlem Ozdemir-Isik⁴, Muhammet Emin Kutu⁵, Ozlem Karakas⁶, Tuba Demirci-Yildirim⁷, Zeliha Ademoglu⁸, Elif Ediboglu⁹, Burcu Ceren Uludogan¹⁰, Nazife Sule yaşar Bile¹⁰, Timucin Kasifoglu¹¹, Servet Akar¹², Hakan Emmungil⁸, Fatos Onen⁷, Ahmet Omma¹³, Nilüfer Alpay Kanıtez¹⁴, Ayten Yazici¹⁵, Ayse Cefle¹⁵, Murat Inanc³, Kenan Aksu¹⁶, Gokhan Keser¹⁷, Haner Direskeneli¹⁸ and Fatma Alibaz Öner¹⁸, ¹Bahcesehir University Faculty of Medicine, Istanbul, Turkey, ²Ottawa University, Ottawa, ON, Canada, ³Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Kocaeli University Faculty of Medicine, Kocaeli, Turkey, ⁵Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey, ⁶Ankara City Hospital, Ankara, Turkey, ⁷Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ⁸Trakya University, Edirne, Turkey, ⁹Mayo Clinic, Rochester, MN, ¹⁰Osmangazi University Faculty of Medicine, Rheumatology, Eskişehir, Turkey, Eskisehir, Turkey, ¹¹Osmangazi University Faculty of Medicine, Eskisehir, Turkey, ¹²Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ¹³Ankara Bilkent City Hospital, Ankara, Turkey, ¹⁴Koc University Faculty of Medicine, Rheumatology, İstanbul, Turkey, Istanbul, Turkey, ¹⁵Kocaeli University Faculty of Medicine, Kocaeli, Turkey, Kocaeli, Turkey, ¹⁶Ege University Faculty of Medicine, Izmir, Turkey, ¹⁷Ege University School of Medicine, Rheumatology, İzmir, Turkey, Izmir, Turkey, ¹⁸Marmara University Faculty of Medicine, Rheumatology, İstanbul, Turkey, Istanbul, Turkey
Background/Purpose: There is no data on which patients biologic immunosuppressive (bIS) treatment should be chosen in Takayasu’s arteritis (TAK). In this study we aimed to…
Abstract Number: 0726 • ACR Convergence 2024
Management of ANCA Vasculitis-Associated Orbital Inflammatory Disease: A Systematic Literature Review
Emma Neary¹, Katie Healey², Marie Clements-Baker³, Jean-Paul Makhzoum⁴ and Arielle Mendel⁵, ¹McGill University, Montreal, QC, Canada, ²Memorial University of Newfoundland, St. John's, NL, Canada, ³Queen's University, Kingston, ON, Canada, ⁴Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁵McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Ocular manifestations are common in ANCA-associated vasculitides (AAV), with orbital inflammatory disease (OID) representing a significant subset. Despite being a vision-threatening complication, OID remains…
Abstract Number: 0762 • ACR Convergence 2024
Different Giant Cell Arteritis Phenotypes May Present Distinct Types of Ischemic Complications
Helena M Amar Muñoz¹, Juan Molina-Collada¹, Isabel Castrejon², irene monjo³, Elisa Fernández-Fernández:⁴, José María Álvaro-Gracia⁵ and Eugenio De Miguel⁶, ¹Hospital General Universitario Gregorio Marañón, MADRID, Spain, ²Hospital General Universitario Gregorio Marañon, Madrid, Spain, ³University Hospital La Paz, Madrid, Spain, ⁴La Paz University Hospital, Alcalá de Henares, Madrid, Spain, ⁵Hospital Gregorio Marañón, Madrid, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: To determine if the subtype of vascular ultrasound (US) presentation is associated with different types of ischemic complications (IC) in giant cell arteritis (GCA).Methods: Retrospective…
Abstract Number: 1107 • ACR Convergence 2024
Investigating Pyrexia of Unknown Origin: A Rheumatologist’s Perspective
Carine Moezinia¹, Jan Nouza², Beatrice Hornstein-Lasry², Luai Kawar², Asim Khan² and Jessica Manson², ¹University College London Hospital, London, England, United Kingdom, ²University College London Hospital, London, United Kingdom
Background/Purpose: Pyrexia of Unknown Origin (PUO) is defined as a fever above 38.3°C recorded on several occasions, that evades diagnosis for at least 3 weeks.…
Abstract Number: 1623 • ACR Convergence 2024
Sex Differences in Phenotypes and Imaging Examination in Giant Cell Arteritis: Data from the ARTESER Registry
Delia Fernández-Lozano¹, Marta Domínguez-Álvaro², Javier Narvaez-García³, Noemí Garrido-Puñal⁴, Eugenio De Miguel⁵, Paula Estrada-Alarcón⁶, Iñigo Hernández-Rodríguez⁷, Maite Silva-Diaz⁸, Joaquín M Belzunegui⁹, Clara Moriano¹⁰, Julio Sánchez-Martín¹¹, Itziar Calvo¹², Vicente Aldasoro¹³, lydia Abasolo Alcazar¹⁴, Javier Loricera¹⁵, Patricia Moya¹⁶, María García-Villanueva¹⁷, Fernando Sánchez-Alonso², Santos Castañeda¹⁸, José L. Hernández¹⁹ and Ricardo Blanco-Alonso²⁰, and ARTESER Project Collaborative Group, ¹Hospital Clínico Universitario de Valencia, Valencia, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ⁷Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁸Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁹Hospital Universitario Donostia, San Sebastián, Spain, ¹⁰Hospital León, LEON, Spain, ¹¹Hospital Universitario 12 de Octubre, Madrid, Spain, ¹²Hospital Universitario de Basurto, Bilbao, Spain, ¹³Hospital Universitario de Navarra, Pamplona, Spain, ¹⁴IdISSC. HCSC, Madrid, Spain, ¹⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ¹⁶Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁷Hospital Ramón y Cajal, MADRID, Madrid, Spain, ¹⁸Hospital Universitario de la Princesa, Madrid, Spain, ¹⁹University of Cantabria. IDIVAL, Santander, Spain, ²⁰Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Giant cell arteritis (GCA) is a predominantly female vasculitis. There are several studies that attempt to report the differences in the presentation of this…
Abstract Number: 1983 • ACR Convergence 2024
Immune Checkpoint Inhibitor Associated Vasculitis and Polymyalgia Rheumatica: A Systematic Review
Aaron Teel¹, Adrian Grebowicz², Mats Junek³, Stephanie Garner⁴, Tom Appleton⁵ and Faiza Khokhar⁶, ¹London Health Sciences Centre, Sarnia, ON, Canada, ²Western University, London, ON, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵The University of Western Ontario, London, ON, Canada, ⁶McMaster University, St. Joseph's Hamilton, Mississauga, ON, Canada
Background/Purpose: Immune checkpoint inhibitors (ICIs) are a class of cancer immunotherapy that have been associated with immune-related adverse events (irAEs). These include multiple rheumatic diseases…
Abstract Number: 2500 • ACR Convergence 2024
Description of Patients with Refractory Kawasaki Disease at a Large Tertiary Center
Jessica Nguyen¹, Danielle Guffey², Andrea Ramirez¹, Jamie Lai³, Tiphanie Vogel¹, S. Kristen Sexson Tejtel¹, Cagri Yildirim-Toruner⁴ and Marietta DeGuzman¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, ³Baylor College of Medicine, The Woodlands, TX, ⁴Baylor College of Medicine/ Texas Children's Hospital, Houston, TX
Background/Purpose: Kawasaki disease (KD) is the leading cause of acquired heart disease in developed countries due to the development of coronary artery aneurysms (CAAs). Intravenous…
Abstract Number: 2526 • ACR Convergence 2024
Development of the Hospital Emergency Advocacy & Treatment Kit (HEAT Kit) for Patients with Vasculitis
Sarah Jones¹, Pamela Squires² and Donna McArthur³, ¹Eosinophilic & Rare Disease Cooperative, Tucson, AZ, ²Eosinophilic & Rare Disease Cooperative, Tucson, ³Adjunct professor of nursing, Vanderbilt School of Nursing; Adjunct clinical professor, University of Arizona College of Nursing & Dept. of Neurology, Tucson, AZ
Background/Purpose: All forms of vasculitis are rare with patients frequently experiencing poor or extended care in the hospital and ED settings. The ERDC founder experienced…
Abstract Number: 0731 • ACR Convergence 2024
Differentiating Primary Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis from Secondary Forms
Adil Vural¹, Kinanah Yaseen², Cassandra Calabrese³ and Adam Brown⁴, ¹Cleveland Clinic, Avon, OH, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic Foundation, Cleveland Heights, OH, ⁴Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: ANCA associated vasculitis (AAV) is a severe autoimmune disorder with substantial morbidity and mortality. Establishing the diagnosis might be challenging due to the existence…
Abstract Number: 0764 • ACR Convergence 2024
Primary Treatment Failure to Tocilizumab in Giant Cell Arteritis
Paul Cioni¹, Hubert de Boysson², Simon Parreau³, Perrine SMETS⁴, Maxime SAMSON⁵, Sara Melboucy⁶, Herve Lobbes⁷, Nabil Belfeki⁸, François Perrin⁹, Pascal Maurice Rossi¹⁰, Eric Liozon¹¹, Guillaume Le Guenno¹², Claire Le Jeunne¹, OLIVIER FOGEL¹³, Lola Prat¹⁴, Florent Ladouce¹⁵, Sylvie Grosleron¹⁶, Halil Yildiz¹⁷, Vincent Grosbost¹⁵, Xavier Puéchal¹⁸, Chloe Comarmond¹⁹ and Benjamin Terrier²⁰, ¹Cochin University Hospital, Paris, France, ²Caen university Hospital, Caen, France, ³Dupuytren hospital, Limoges, France, ⁴Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, ⁵Dijon University Hospital, Dijon, France, ⁶CH Saint Quentin, Saint Quentin, France, ⁷CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁸GHSIF - Melun, Melun, France, ⁹CH Saint Nazaire, Saint Nazaire, France, ¹⁰CHU Hopital Nord Marseille, Marseille, France, ¹¹CHU Limoges, Limoges, France, ¹²CHU, Clermont-Ferrand, France,, Clermont-Ferrand, France, ¹³AP-HP, Paris, France, ¹⁴Jacques Cartier Hospital, Massy, France, ¹⁵Clermont Ferrand University Hospital, Clermont Ferrand, France, ¹⁶CH Agen-Nerac, Agen, France, ¹⁷Saint-Luc University Clinic, Bruxells, Belgium, ¹⁸National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ¹⁹Lariboisière University Hospital, Paris, France, ²⁰Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Giant cell arteritis (GCA) is the most common vasculitis in people over the age of 50. Glucocorticoids are the cornerstone of treatment for GCA,…
Abstract Number: 1294 • ACR Convergence 2024
Using Case-Based Continuing Education to Identify and Address Knowledge and Behavior Gaps in ANCA-associated Vasculitis
Bharati Hegde, Jillian Scavone, Katie Robinson and Robert Esgro, Vindico Medical Education, West Deptford, NJ
Background/Purpose: Given the rarity and non-specific symptoms associated with ANCA-associated vasculitis (AAV), rheumatology clinicians are challenged to use best practices for patient recognition and management,…
Abstract Number: 1624 • ACR Convergence 2024
Prognostic Value of Baseline 18F-FDG PET/CT Scan in Giant Cell Arteritis with Large Vessel Involvement
Julio Sánchez-Martín¹, Javier Loricera², Isabel Martinez-Rodriguez³, ivan Ferraz-Amaro⁴, Nestor Martinez-Amador⁵, Remedios Quirce-Pisano⁵, Fernando Lopez-Gutierrez⁶ and Ricardo Blanco-Alonso⁷, ¹Hospital Universitario 12 de Octubre, Madrid, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Nuclear Medicine, Hospital Universitario Marques de Valdecilla,IDIVAL, Santander, Cantabria, Spain, ⁴Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁵Department of Nuclear Medicine, Hospital Universitario Marqués de Valdecilla, Molecular Imaging Group, IDIVAL, Santander., Santander, Spain, ⁶Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ⁷Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) scan has become a very useful diagnostic tool in patients with GCA with large vessel involvement. However,…
Abstract Number: 1986 • ACR Convergence 2024
Disease Flare Following Immune Checkpoint Inhibition in Patients with Cancer and Preexisting Vasculitis
Juan Sevillano¹, Yixuan Zhou², Juan Ruiz³, Noha Abdel-Wahab⁴ and Maria Suarez-Almazor¹, ¹MD Anderson Cancer Center, Houston, TX, ²Baylor College of Medicine, Houston, ³MD Anderson, Houston, TX, ⁴University of Texas MD Anderson Cancer Center, houston, TX
Background/Purpose: Immune checkpoint inhibitors (ICI) are effective therapies for patients with cancer, but they often cause immune-related adverse events (irAE). There is limited data on…
Abstract Number: 2501 • ACR Convergence 2024
Long-term Remission off Therapy (LTROT) Is Possible in Non-infectious Aortitis with DMARDs with Low Risk of Secondary Adrenal Insufficiency
Rohit Vijjhalwar¹, Vithushanan Ketheeswaranathan², Aman More², Rajinder Andev³ and Shirish Dubey⁴, ¹University of Oxford, Staines, United Kingdom, ²Medical Sciences Division, University of Oxford, Oxford, United Kingdom, ³Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom, ⁴Oxford University Hospitals NHS FT, Oxford, United Kingdom
Background/Purpose: Non-infectious Aortitis is a rare form of large vessel vasculitis which has a high risk of complications1. There is limited data on the management…

« Previous Page
1
…
6
7
8
9
10
…
41
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].